poster

Effects of Solriamfetol on Driving Performance in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea

Introduction: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved (US and EU) to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA;...

10/08/2020

Effect of Benzodiazepines on Esketamine Nasal Spray for Treating Patients With Major Depressive Disorder With Active Suicidal Ideation and Intent

Aim: To examine potential effects of concomitant benzodiazepines on the safety and efficacy of esketamine nasal spray following first-dose treatment of patients in urgent need of symptom ...

10/08/2020

Concerns from Community Mental Health Center (CMHC) Patients Regarding Drug-Induced Movement Disorders: Impact on Functioning and Treatment Beliefs

Background: Drug-induced movement disorders (DIMDs) may occur in patients treated with antipsychotics. The CommonGround Program supports the recovery and healing of psychiatric outpatient...

10/08/2020

Effect of Lemborexant Treatment Across 12 Months on Fatigue Severity and Sleep Outcomes in Subjects With Clinically Significant Fatigue at Baseline

Introduction: The Fatigue Severity Scale (FSS) assesses impact of fatigue on patients’ lives. Lemborexant (LEM) efficacy was examined in the subgroup of subjects with baseline FSS total s...

10/08/2020

All-cause Healthcare Resource Utilization and Costs Among Patients With Episodic or Chronic Migraine and Comorbid Depression and/or Anxiety

Objective: This real-world retrospective cohort study evaluated healthcare resource utilization (HCRU) and costs for adult patients with episodic migraine (EM) or chronic migraine (CM) an...

10/08/2020

Antidepressant and Psychotherapy Treatment among Patients With Major Depressive Disorder and an Elevated PHQ-9 Score

Background The PHQ-9 measures depression symptom severity and is recommended for use in clinical practice among patients with major depressive disorder (MDD). Objective To describe treat...

10/08/2020

An Assessment of the Impact of Prior Antipsychotic Treatment on the Duration of Treatment with RBP-7000 during a Long-Term Safety Study

Introduction: RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved for the treatment of schizophrenia in adults, designed to deliver clini...

10/08/2020

Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting

BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited. METHODS: Adu...

10/08/2020

Bipolar Disorder Treatment Patterns in the United States: A Retrospective Claims Database Study

Background: The objective of this retrospective study was to describe treatment patterns among patients with bipolar disorder.

10/08/2020

Characteristics of young adults with schizophrenia using Colorado`s All Payer Claims Database (CO-APCD)

Background Schizophrenia (SCZ) is most likely to develop in young adulthood. Using data from a single state, we describe the demographic and clinical characteristics of young adults in t...

10/08/2020

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products